Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …
treatment of malignancies across a broad range of indications. Whereas initially, single …
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …
GD2-CART01 for relapsed or refractory high-risk neuroblastoma
Background Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells that
target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for …
target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for …
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …
Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results
Vα24-invariant natural killer T cells (NKTs) have anti-tumor properties that can be enhanced
by chimeric antigen receptors (CARs). Here we report updated interim results from the first-in …
by chimeric antigen receptors (CARs). Here we report updated interim results from the first-in …
Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity
Chimeric antigen receptor (CAR) T cell therapy is revolutionizing cancer immunotherapy for
patients with B cell malignancies and is now being developed for solid tumors and chronic …
patients with B cell malignancies and is now being developed for solid tumors and chronic …
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Due to their efficient recognition and lysis of malignant cells, natural killer (NK) cells are
considered as specialized immune cells that can be genetically modified to obtain capable …
considered as specialized immune cells that can be genetically modified to obtain capable …
CAR T cell therapy for solid tumors: bright future or dark reality?
Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …
its success for hematological malignancies in clinical studies leading to the US Food and …
Clinical lessons learned from the first leg of the CAR T cell journey
Chimeric antigen receptor (CAR) T cell therapy for B cell malignancies has surpassed
expectations, driving an ever-expanding number of clinical trials and the first US Food and …
expectations, driving an ever-expanding number of clinical trials and the first US Food and …
Tumor antigen escape from CAR T-cell therapy
Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …
demonstrate that a common mechanism of resistance to this novel class of therapeutics is …